82 related articles for article (PubMed ID: 9762674)
1. In vitro cytokine profiles as indicators of relapse activity and clinical course in multiple sclerosis.
Schluep M; van Melle G; Henry H; Städler C; Roth-Wicky B; Magistretti PJ
Mult Scler; 1998 Jun; 4(3):198-202. PubMed ID: 9762674
[TBL] [Abstract][Full Text] [Related]
2. Assessing multiple sclerosis activity: is the in vitro production of tumor necrosis factor-alpha, interleukins 2, 6, 4, and 10, and immunoglobulin G of value?
Schluep M; van Melle G; Henry H; Städler C; Roth-Wicky B; Magistretti PJ
J Neurol; 1999 Nov; 246(11):1041-50. PubMed ID: 10631636
[TBL] [Abstract][Full Text] [Related]
3. Tumor necrosis factor-alfa and interleukin-4 in cerbrospinal fluid and plasma in different clinical forms of multiple sclerosis.
Obradović D; Kataranovski M; Dincić E; Obradović S; Colić M
Vojnosanit Pregl; 2012 Feb; 69(2):151-6. PubMed ID: 22500369
[TBL] [Abstract][Full Text] [Related]
4. Effects of interferon beta, cyclophosphamide and azathioprine on cytokine profile in patients with multiple sclerosis.
Totaro R; Passacantando A; Russo T; Parzanese I; Rascente M; Marini C; Tonietti G; Carolei A
Int J Immunopathol Pharmacol; 2005; 18(2):377-83. PubMed ID: 15888259
[TBL] [Abstract][Full Text] [Related]
5. Stimulated PBMC-produced IFN-γ and TNF-α are associated with altered relapse risk in multiple sclerosis: results from a prospective cohort study.
Simpson S; Stewart N; van der Mei I; Otahal P; Charlesworth J; Ponsonby AL; Blizzard L; Dwyer T; Pittas F; Gies P; Taylor B
J Neurol Neurosurg Psychiatry; 2015 Feb; 86(2):200-7. PubMed ID: 24790215
[TBL] [Abstract][Full Text] [Related]
6. [T-cell interferon-gamma, tumor necrosis factor-alpha and interleukin-6 receptor binding in patients with multiple sclerosis. Effects of interferon-beta-1b treatment].
Bongioanni P; Romano MR; Boccardi B; Lombardo F; Moscato G; Mosti S; Baldini C; Nuti S; Meucci G; Rossi B
Rev Neurol; 1999 Nov 16-30; 29(10):893-9. PubMed ID: 10637835
[TBL] [Abstract][Full Text] [Related]
7. [Immunogenetic cytokine restriction in multiple sclerosis].
Odinak MM; Bisaga GN; kalinina NM; Akimov SB; Davydova NI
Zh Nevrol Psikhiatr Im S S Korsakova; 2001; 101(9):39-44. PubMed ID: 11586702
[TBL] [Abstract][Full Text] [Related]
8. Variations of IL2, IL6, TNF alpha plasmatic levels in relapsing remitting multiple sclerosis.
Hautecoeur P; Forzy G; Gallois P; Demirbilek V; Feugas O
Acta Neurol Belg; 1997 Dec; 97(4):240-3. PubMed ID: 9478261
[TBL] [Abstract][Full Text] [Related]
9. Short-term treatment of relapsing remitting multiple sclerosis patients with interferon (IFN)-beta1B transiently increases the blood levels of interleukin (IL)-6, IL-10 and IFN-gamma without significantly modifying those of IL-1beta, IL-2, IL-4 and tumour necrosis factor-alpha.
Nicoletti F; Di Marco R; Patti F; Zaccone P; L'Episcopo MR; Reggio E; Xiang M; Nicoletti A; Reggio A
Cytokine; 2000 Jun; 12(6):682-7. PubMed ID: 10843745
[TBL] [Abstract][Full Text] [Related]
10. Tumor necrosis factor alpha production as a possible predictor of relapse in patients with multiple sclerosis.
Chofflon M; Juillard C; Juillard P; Gauthier G; Grau GE
Eur Cytokine Netw; 1992; 3(6):523-31. PubMed ID: 1296800
[TBL] [Abstract][Full Text] [Related]
11. IFN-beta 1b treatment of relapsing multiple sclerosis has no effect on CD3-induced inflammatory or counterregulatory anti-inflammatory cytokine secretion ex vivo after nine months.
Brod SA; Nelson LD; Khan M; Wolinsky JS
Int J Neurosci; 1997 Jun; 90(1-2):135-44. PubMed ID: 9285295
[TBL] [Abstract][Full Text] [Related]
12. Tumor necrosis factor production capacity as a potentially useful parameter to monitor disease activity in multiple sclerosis.
Chofflon M; Roth S; Juillard C; Paunier AM; Juillard P; Degroote D; Grau GE
Eur Cytokine Netw; 1997 Sep; 8(3):253-7. PubMed ID: 9346357
[TBL] [Abstract][Full Text] [Related]
13. Relapse markers in multiple sclerosis: are in vitro cytokine production changes reflected by circulatory T-cell phenotype alterations?
Debruyne J; Philippé J; Dereuck J; Willems A; Leroux-Roels G
Mult Scler; 1998 Jun; 4(3):193-7. PubMed ID: 9762673
[TBL] [Abstract][Full Text] [Related]
14. Synergistic immunomodulatory effects of interferon-beta1b and the phosphodiesterase inhibitor pentoxifylline in patients with relapsing-remitting multiple sclerosis.
Weber F; Polak T; Günther A; Kubuschok B; Janovskaja J; Bitsch A; Poser S; Rieckmann P
Ann Neurol; 1998 Jul; 44(1):27-34. PubMed ID: 9667590
[TBL] [Abstract][Full Text] [Related]
15. Genetic variation in PBMC-produced IFN-γ and TNF-α associations with relapse in multiple sclerosis.
Zhou Y; Taylor B; van der Mei I; Stewart N; Charlesworth J; Blizzard L; Ponsonby AL; Dwyer T; Pittas F; Simpson S
J Neurol Sci; 2015 Feb; 349(1-2):40-4. PubMed ID: 25575858
[TBL] [Abstract][Full Text] [Related]
16. Beneficial effect of interferon-beta treatment in patients with multiple sclerosis is associated with transient increase in serum IL-6 level in response to interferon-beta injection.
Nakatsuji Y; Nakano M; Moriya M; Kishigami H; Tatsumi C; Tada S; Sadahiro S; Naka T; Mitani K; Funauchi M; Azuma T; Watanabe S; Kinoshita M; Kajiyama K; Yuasa Y; Kaido M; Takahashi MP; Naba I; Hazama T; Sakoda S;
Cytokine; 2006 Oct; 36(1-2):69-74. PubMed ID: 17161613
[TBL] [Abstract][Full Text] [Related]
17. Expression of TNF-alpha mRNA by peripheral blood mononuclear cells of multiple sclerosis patients treated with IFN-beta 1A.
Sarchielli P; Critelli A; Greco L; Sokola E; Floridi A; Gallai V
Cytokine; 2001 Jun; 14(5):294-8. PubMed ID: 11444910
[TBL] [Abstract][Full Text] [Related]
18. The phosphodiesterase i.v. inhibitor rolipram in vitro reduces the numbers of MBP-reactive IFN-gamma and TNF-alpha mRNA expressing blood mononuclear cells in patients with multiple sclerosis.
Navikas V; Matusevicius D; Söderström M; Pirskanen R; Fredrikson S; Link H
Clin Neuropharmacol; 1998; 21(4):236-44. PubMed ID: 9704165
[TBL] [Abstract][Full Text] [Related]
19. Intracellular cytokine profile in T-cell subsets of multiple sclerosis patients: different features in primary progressive disease.
Killestein J; Den Drijver BF; Van der Graaff WL; Uitdehaag BM; Polman CH; Van Lier RA
Mult Scler; 2001 Jun; 7(3):145-50. PubMed ID: 11475436
[TBL] [Abstract][Full Text] [Related]
20. Cytokine production profiles in chronic relapsing-remitting experimental autoimmune encephalomyelitis: IFN-γ and TNF-α are important participants in the first attack but not in the relapse.
Hidaka Y; Inaba Y; Matsuda K; Itoh M; Kaneyama T; Nakazawa Y; Koh CS; Ichikawa M
J Neurol Sci; 2014 May; 340(1-2):117-22. PubMed ID: 24655735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
